cd8α microbeads (Miltenyi Biotec)
Structured Review
Cd8α Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd8a+microbeads/StraightFrom+Spleen+CD8a+MicroBead+Kit%2C+mouse/pm40523938-321-20-22
Average 93 stars, based on 1 article reviews
Images
Related Articles
Single Cell:Article Title: A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Article Snippet: Residual cancer stem-like cells (CSCs) can cause tumour recurrence within a narrow margin around the initial tumour resection lesion, increasing the risk of post-surgical relapse and incurability.. Currently, there are no efficient strategies for tracking and eradicating CSCs.. Here we propose a nanovaccine strategy, called NICER, based on a nanovesicle system integrating CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer, to simultaneously eradicate CSCs and bulk tumour cells. Suspension:Article Title: A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Article Snippet: Residual cancer stem-like cells (CSCs) can cause tumour recurrence within a narrow margin around the initial tumour resection lesion, increasing the risk of post-surgical relapse and incurability.. Currently, there are no efficient strategies for tracking and eradicating CSCs.. Here we propose a nanovaccine strategy, called NICER, based on a nanovesicle system integrating CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer, to simultaneously eradicate CSCs and bulk tumour cells. Isolation:Article Title: A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Article Snippet: Residual cancer stem-like cells (CSCs) can cause tumour recurrence within a narrow margin around the initial tumour resection lesion, increasing the risk of post-surgical relapse and incurability.. Currently, there are no efficient strategies for tracking and eradicating CSCs.. Here we propose a nanovaccine strategy, called NICER, based on a nanovesicle system integrating CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer, to simultaneously eradicate CSCs and bulk tumour cells. |


